Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER acutely exacerbated subjects with schizofrenia.
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2012
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PERTAIN
- Sponsors Janssen-Cilag
- 10 Jun 2017 Biomarkers information updated
- 12 Jul 2011 This trial is completed in Italy, Lithuania, Germany.
- 12 Jul 2011 New trial record